Micro cell vesicle technology (mCVT): a novel hybrid system of gene delivery for hard-to-transfect (HTT) cells

A hybrid gene delivery platform, micro Cell Vesicle Technology (mCVT), produced from the fusion of plasma membranes and cationic lipids, is presently used to improve the transfection efficiency of hard-to-transfect (HTT) cells. The plasma membrane components of mCVTs impart specificity in cellular u...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale 2020-09, Vol.12 (35), p.1822-183
Main Authors: Ou, Yi-Hsuan, Zou, Shui, Goh, Wei Jiang, Chong, Suet Yen, Venkatesan, Gopalakrishnan, Wacker, Matthias G, Storm, Gerrit, Wang, Jiong-Wei, Czarny, Bertrand, Pastorin, Giorgia, Woon, Esther C. Y
Format: Article
Language:English
Subjects:
Cations
Gene Transfer Techniques
Hybrid systems
Lipids
Membranes
Structural integrity
Technology
Toxicity
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A hybrid gene delivery platform, micro Cell Vesicle Technology (mCVT), produced from the fusion of plasma membranes and cationic lipids, is presently used to improve the transfection efficiency of hard-to-transfect (HTT) cells. The plasma membrane components of mCVTs impart specificity in cellular uptake and reduce cytotoxicity in the transfection process, while the cationic lipids complex with the genetic material and provide structural integrity to mCVTs. A new hybrid gene delivery platform (mCVT) remarkably improves the transfection efficiency of hard-to-transfect (HTT) cells, while preserving excellent biocompatibility.
ISSN:2040-3364
2040-3372
DOI:10.1039/d0nr03784b